Clinical Trial Update: A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma [Phase 2]

View source ↗

Summary

Open-label Phase 2 study of IMC-A12 (cixutumumab) in advanced sarcomas. Results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Leiomyosarcoma
• Liposarcoma
• Peripheral Neuroectodermal Tumor
• Rhabdomyosarcoma
• Synovial Sarcoma

Drugs mentioned

• IMC-A12 (cixutumumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET), Rhabdomyosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2018-07-17